ASCO 2025 ProstACT Global, phase 3 study of 177Lu-rosptamab + standard of care versus standard of care alone, metastatic castration-resistant prostate cancer (mCRPC).

PSMA and Beyond 2025 PSMAfore trial, SPLASH trial, ECLIPSE trial, PSMA radioligand therapy, PSMAfore compared to SPLASH, SPLASH LuPSMA arm, PSMAfore LuPSMA arm, ProstACT GLOBAL.

Final overall survival and safety analyses of the phase 3 PSMAfore trial of [177Lu]Lu-PSMA-617 versus change of androgen receptor pathway inhibitor in taxane-naive patients with metastatic ...

(UroToday.com) The 2025 European Association of Urology (EAU) Annual Congress held in Madrid, Spain, between March 21 st and 24 th 2025, was host to a thematic session on hot topics in the management ...

PSMA and Beyond 2025 antibody drug development (ADC) in prostate cancer, ADC program in advance prostate cancer, PSMA expression, ...

The 34rd World Congress of Endourology (WCE) held in Conjunction with the South African Urological Association (SAUA) Meeting in 2016 was held in Cape Town, South Africa from November 8th-12th, 2016.

UroToday - GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.

ASCO 2025, prostate cancer, radioligand therapy (RLT), Radioligand Therapies in Prostate Cancer, Prostate-Specific Membrane Antigen Ligand Positron Emission Tomography (PSMA-PET), 177Lu-PSMA-617.

ASCO 2025 BULLSEYE trial, Prostate-Specific Membrane Antigen (PSMA) Radioligand Therapy, androgen deprivation therapy (ADT), 177Lu-PSMA-617, PSMAddition.

ASCO GU 2025, metastatic castration resistant prostate cancer (mCRPC), Precision Diagnostics in Prostate Cancer Treatment (PREDICT): PREDICT trial, Alliance A032102, H3 lysine 27 methylation (H3K27me) ...

AUA 2025, penile fracture, AUA Guidelines for penile fractures, intralesional Collagenase Clostridium Histolyticum therapy (CCH), Peyronie’s Disease (PD), IMPRESS Trials.

ASCO 2025, Nivolumab plus ipilimumab vs sunitinib, casdatifan plus cabozantinib, Hypoxia-inducible factor-2α (HIF-2α) inhibitor belzutifan, ALLO-316 in advanced clear cell renal cell carcinoma (ccRCC) ...